Investor Presentation

November 2021

HOLISTA COLLTECH

Company Overview (ASX: HCT) World-leading technologies & global reach

Holista Colltech is an emerging Australian developer of unique health and wellness products in the US\$4.5 trillion Global Health and Wellness Industry (see Note 1)


Note 1 :https://globalwellnessinstitute.org/press-room/statisticsand-facts/

Key Market Stats*	
Market Cap	\$14.9m
52-week Trading Range	4.8¢ - 9.3¢
Average Daily Vol.	259,470
No. of Shares on Issue	275.4m
Top 20 Shareholders	68%
*As of 10/11/21	

- Successfully commercialised portfolio of patentprotected/proprietary technologies
- Established track record with ~\$7m in annual sales
- Key products include low-GI food ingredients used by leading food manufacturers, all-natural sanitisers for consumer and industrial applications, market leading dietary supplements and disease-free ovine Collagen.



Year of Achievements Foundations for a stronger FY22



Business Divisions Growth engines



Healthy Food Ingredients

- Fastest growing division
- Momentum expected to continue
- GI Lite[™] for healthier breads, tortilla, etc
- 80Less[™] sugar substitute, tapping on increasing awareness danger of sugar



Infection Control Solutions



Newest business (FY20 1st year contribution)
Strong multi-year growth potential
Patented allnatural sanitisers
Unique delivery via HVAC systems via patented M3® technology
Patented nasal balm formulation Supplements

Dietary



strongly from COVID-19

impact

• Market leading vitamin brand in Malaysia



Ovine Collagen

1st to produce ovine collagen from Australian Sheep
Patented processes
Australian

collagen highly sort after due to disease-free status

• Product sold to cosmetics manufacturers



Food Ingredients Developments & update



Muffins, white breads and pasta made with GI Lite[™] scored a GI reading of 48, 46 and 38 respectively Sales increased by 45% Q3 2021 v Q3 2020, driven by GI Lite™ and 80Less™

Growth driven by Costanzo's orders despite pandemic in USA

Stronger growth expected with Costanzo's official launch in December 2021

Partnership with Berjaya's Country Farms opens opportunities into several leading franchises in Malaysia (e.g. Starbucks, Kenny Rogers and 7-Eleven)





Infection Control Developments & update





6



Natshield™ received Trademark approval for sales in China

Persistence tests proof Natshield[™] lasts up to 12 hours on skin and hard surface


Launching world's first Nasal Protecting Balm active for 12 hours in Q4 2021 in Malaysia, US and South America

Securing test kit opportunities in the US, South America and UK (pending regulatory approvals)





Infection Control Natshield™ Nasal Protecting Balm





Persistence tests prove Natshield™ lasts up to 12 hours on skin and hard surface by SGS and Chemlab in Malaysia

Nasal protecting balm formulated to be PH 5.5 which prevents pathogen growth on skins*

Contains 5% Path-Away® / Protectene™ that has been proven to kill SARS-CoV-2 99.9% within 2 minutes

Launch in North America by Igalen in Q4 Pending registration in Latin American countries staring with Columbia

* Source : https://www.usgs.gov/media/images/ph-describes-acidity-aqueous-liquid





Dietary Supplements Developments & update









Double digit growth in Sales Q3 2021 v Q3 2020

Growth driven by rebound from COVID and launch of new supplement (Hydro D – water soluble Vitamin D)

"Cash Cow" business that contributed ~70% of 2021 Group revenue with market leading products

Global Supplement market growing at 8.6% CAGR* from 2021-2028*

* Source: https://www.grandviewresearch.com/industry-analysis/dietary-supplements-market



Ovine Collagen Developments & update

Guangzhou Sinbio Cosmetic Co Ltd is a Chinese stateowned enterprise that exclusively represents leading cosmetic brands like Ceeture, Estee Lauder and SK-II China. Guangzhou Sinbio sells cosmetics via a network of 45,000 directowned stores.



9 Investor Presentation November 2021

World's 1st and only company to extract ovine collagen from Australian sheep

Production facility in Collie, Western Australia using patented technology to produce premium grade ovine collagen

Guangzhou Sinbio to purchase most of Holista's annual productions upon successful conclusion of trials

Binding sales agreement to see Holista expand plant capacity over the next four years





Unlocking Value for Ovine Collagen Significant growth options





Outlook ³oadmar

Roadmap to growth

Positive Outlook Improved 2022 results expected

- Multiple Growth Levers: Several significant growth opportunities that can lead to a significant step-change in earnings over short- to medium-term
- Improved Outlook: Trading conditions in 2021 show marked improvement over previous year
- Expanding Margins: Profit margins expected to improve on 2021 due to cost optimisation and organic growth
- ✓ Positive Tailwinds: Global trends supportive of further growth over medium- to longer-term for all divisions

Healthy Food

- Improved demand for GI-Lite[™] and 80Less[™]
- Growing consumer focus on healthier foods to drive growth
- Trials with Berjaya's Country Farms ongoing
- Costanzo's launching big promotional campaign in US for GI Lite™ bread

Infection Control

- Sales of Natshield[™] sanitisers expected to continue to grow
- New product launches and potential expansion into China to fuel next phase of growth
- Successful persistence testing will bolster demand for NatshieldTM

Dietary Supplements


- Sales up double-digit & further growth expected in 2022
- New products contributing to growth
- Will remain a significant cash generator for Holista

Ovine Collagen

- Potentially a transformative deal with China
- Major plant expansion when agreement becomes binding
- Capex fully funded from customer deposits, grants and internal resources



Investment Proposition Well-positioned for growth





Multiple growth avenues with defensive revenue streams



Global reach with proven products sold around the world



Large addressable and growing markets in health/wellness



Positive outlook with further growth momentum expected



Improved results expected and ready for 2022 prospects



Board of Directors & Advisors Expertise to lead the group forward



Rajen Manicka Executive Chairman MD & CEO

Dr Rajen spent nine years working for Big Pharma including Roche and CIBA Pharmaceuticals in various capacities including product and marketing manager. He is a prominent figure in the Malaysian biotech industry and is a member of the Malaysian Ministry of Health Standing Committee for Traditional Medicine.



Walter Joseph Non-Executive Director

Successful track record working in senior management and consulting positions over the past five decades at several leading organizations, including the National Australia Bank, Wesfarmers-Bunnings, P&O Ports, Water Corporation of Western Australia (WA) and the WA Department of Commerce and Trade.

14 Investor Presentation November 2021



Loren King Non-Executive Director

Mrs Loren King has worked in corporate finance and senior administration roles with ASX listed companies, stockbroking and corporate advisory services for the past 15 years. Mrs King has a Bachelor of Psychology, is a Fellow Member of the Governance Institute of Australia holding a Graduate Diploma of **Applied** Corporate Governance and has a Certificate IV in Financial Services (Bookkeeping).



Jay Stephenson Company Secretary

Mr Stephenson has been involved in business development for over 30 years including the past 25 years as Director, Chief Financial Officer and Company Secretary for various listed and unlisted entities He has been involved in business acquisitions, mergers, initial public offerings, capital raisings, business restructuring as well managing all areas of finance for companies.



Arthur Martin Advisor

Founder and President of GICC. Dr Martin invented PathAway® and has conducted over 4.000 assessments for chem biological, bacterial and viral contamination. He pioneered the concept of "Prophylactic Air Management for Pathogen Control" and has an extensive list of publications and peer reviewed awards.



Roscoe Moore Advisor

Dr Moore served as Assistant US Surgeon General, Rear Admiral of U.S. Public Health Service, Chief Epidemiologist with the Center for Device and Radiological Health at the U.S. FDA and Senior Epidemiologist within the National Institute for Occupational Safety and Health, Center for Disease Control (CDC).



Disclaimer



This document has been prepared by Holista Colltech Limited and comprises written material/slides for a presentation concerning Holista Colltech Limited and its subsidiaries. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase, or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

Certain statements in this presentation are forward looking statements. You can identify these statements by the fact that they use words such as "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", "may", "assume" and words of similar import. These forward looking statements speak only as at the date of this presentation. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Holista Colltech Limited that the forward looking statements contained in this presentation are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, Holista Colltech Limited and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss of damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Subject to any continuing obligation under applicable law or any relevant listing rules of the ASX, Holista Colltech Limited disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change of events, conditions, or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Holista Colltech Limited since the date of this presentation.



To join our mailing list please email: <u>update@holistaco.com</u>

Thank You

For further information, please contact:

Corporate Matters: <u>investor@holistaco.com</u> General Enquiries: <u>enquiries@holistaco.com</u> Investor/Media Relations: Brendon Lau (m: 0409 341 613, e: <u>brendon@vantagepointpartners.com.au</u>)

